Vertex Pharmaceuticals' Symdeko, or tezacaftor/ivacaftor and ivacaftor, was approved by the FDA as a treatment for patients at least 12 years of age with cystic fibrosis who have two copies of the F508del mutation in the CFTR gene or at least one mutation that responds to tezacaftor/ivacaftor.
Vertex's cystic fibrosis combo drug approved by FDA
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.